RBC Capital Downgrades Marinus Pharmaceuticals (MRNS) to Sector Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
Go back to RBC Capital Downgrades Marinus Pharmaceuticals (MRNS) to Sector Perform
June 14, 2016 7:23 AM EDT
Oppenheimer downgraded Marinus Pharmaceuticals (NASDAQ: MRNS) from Outperform to Perform.
For an analyst ratings summary and ratings history on Marinus Pharmaceuticals click here. For more ratings news on Marinus Pharmaceuticals click here.
Shares of Marinus Pharmaceuticals closed at $1.62 yesterday.
...
More
June 14, 2016 7:02 AM EDT
Stifel downgraded Marinus Pharmaceuticals (NASDAQ: MRNS) from Buy to Hold and removed its price target (prior $16.00).
For an analyst ratings summary and ratings history on Marinus Pharmaceuticals click here. For more ratings news on Marinus Pharmaceuticals click here.
Shares of Marinus Pharmaceuticals closed at $1.62 yesterday.
...
More
June 13, 2016 11:43 AM EDT
Stifel downgraded Marinus Pharmaceuticals (NASDAQ: MRNS) from Buy to Hold after the company announced that the Phase III study with ganaxolone in focal onset epilepsy patients did not meet the primary endpoint
Analyst Thomas Shrader commented, "As a result Marinus has made the... More
June 13, 2016 7:31 AM EDT
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced top-line results from its Phase 3 clinical trial in adults with drug-resistant focal onset seizures. In this trial, ganaxolone did not meet the primary endpoint of demonstrating a statistically significant difference from placebo. Consistent with previously conducted studies, ganaxolone was generally safe and well tolerated. Marinus plans to discontinue its program in adult focal onset seizures and focus its... More
